HONG KONG DRUG LICENSING
Hong Kong Drug Licence FAQs
Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.
Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.
Official information from the Drug Office Official information from the Chinese Medicines Board
找到 50 条结果，第 3／3 页。每页显示 20 条；无需启用 JavaScript。
Q491 · 如何区分中成药与健康食品在香港的监管分类？独立链接
In Hong Kong, proprietary Chinese medicines are generally regarded as medicines and are regulated under the Pharmacy and Poisons Ordinance (Cap. 138). They require a pharmaceutical licence and must comply with requirements on medicine safety, ingredients and labelling. Health foods do not fall within the category of medicines and are primarily regulated under the Trade Descriptions Ordinance (Cap. 362) and the Food Safety Ordinance (Cap. 612), with an emphasis on food safety and accurate labelling. If a proprietary Chinese medicine contains medicinal ingredients or makes therapeutic claims, it must go through the pharmaceutical licensing approval process; health foods must not claim to treat or prevent disease. Correct classification helps businesses avoid compliance risks.
Q492 · 跨境销售中成药时，香港药牌的管辖范围具体包括哪些？独立链接
Hong Kong’s pharmaceutical licensing regime covers medicines sold, supplied, distributed or displayed in Hong Kong, including proprietary Chinese medicines. Cross-border sales involve importing products into Hong Kong; the medicines must hold valid Hong Kong pharmaceutical licences and comply with local labelling and safety standards. Sales into the Hong Kong market through online platforms are also regarded as supply in Hong Kong and must be compliant. Rengangyongsheng (Hong Kong) Limited assists clients throughout the process with import permits, pharmaceutical licence applications and subsequent compliance oversight, to support the lawful circulation of proprietary Chinese medicines across borders.
Q493 · 仁港永胜（RGYS）如何支持客户实现跨境医药产品一站式合规服务？独立链接
Drawing on extensive industry experience, Rengangyongsheng (Hong Kong) Limited (RGYS) provides end-to-end compliance services covering product classification assessments, medicine licence applications, import customs clearance and labelling reviews. We understand the complexities of cross-border pharmaceutical products under different regulatory systems and help clients develop compliance strategies to reduce approval times. Our team closely monitors the latest policies issued by the Drug Office, Department of Health, and relevant regulators to ensure that clients’ products meet current requirements, helping them enter the Hong Kong market quickly while reducing legal risks.
Q494 · 在香港，健康食品产品标签需要注意哪些合规要点？独立链接
Health food labels in Hong Kong must comply with the requirements of the Trade Descriptions Ordinance (Cap. 362) and the Food Safety Ordinance (Cap. 612). Labels must clearly state the product name, ingredients, net weight, manufacturer and importer information, storage conditions and expiry date. They must not contain medical claims relating to the treatment, diagnosis or prevention of disease. Where Chinese herbal medicine ingredients are involved, their source and quantity should also be stated. Labels should be in Chinese and English to ensure that consumers understand them. Properly compliant labelling not only meets legal requirements but also enhances consumer confidence.
Q495 · 中成药进口至香港时，必须满足哪些主要合规要求？独立链接
When importing proprietary Chinese medicines into Hong Kong, a valid Hong Kong pharmaceutical licence must be held and the import licence requirements under the Pharmacy and Poisons Ordinance (Cap. 138) must be met. Product ingredients, formulae and pharmacological information must be submitted for review by the Drug Office to ensure that the ingredients are safe and the efficacy claims reasonable. Imports must be declared and undergo health inspection. Labels must state the ingredients, directions for use, contraindications and production batch number in both Chinese and English. Rengangyongsheng (Hong Kong) Limited assists clients in preparing complete documents and coordinating imports and pharmaceutical licence applications to help ensure compliant and prompt release.
Q496 · 近年来香港跨境医药行业有哪些重要趋势值得关注？独立链接
In recent years, Hong Kong’s cross-border pharmaceutical industry has seen trends towards digital transformation, tighter regulation and more diverse market demand. With the rise of e-commerce, regulation of online pharmaceutical sales has tightened, bringing stricter requirements for pharmaceutical licences and labelling. At the same time, increased consumer concern about the quality and safety of proprietary Chinese medicines and health products is driving the development of industry standards. Rengangyongsheng (Hong Kong) Limited closely monitors policy developments and helps clients adapt to digital regulatory requirements, bring products to market compliantly and meet changing market needs.
Q497 · 如何有效区分产品是属于药品还是健康食品类别？独立链接
The key to distinguishing medicines from health foods lies in the product’s claims and ingredients. Medicines usually contain active medicinal ingredients and claim to treat, diagnose or prevent diseases, and are regulated under the Pharmacy and Poisons Ordinance (Cap. 138). Health foods are intended to maintain health or supplement nutrition and must not make claims to treat diseases. Rengangyongsheng (Hong Kong) Limited recommends assessing the product category through ingredient analysis and market positioning, together with guidance from the Drug Office, Department of Health, to ensure that the product is promoted lawfully.
Q498 · 仁港永胜如何协助客户应对香港药品监管的最新变革？独立链接
Rengangyongsheng (Hong Kong) Limited closely monitors the latest regulatory and code of practice updates issued by the Drug Office, Department of Health, and relevant departments, and adjusts compliance strategies in a timely manner. We provide clients with regulatory interpretation, compliance training and application document optimisation to ensure that medicine licence applications and renewals meet current requirements. Through data management and tracking systems, we help clients respond efficiently to regulatory changes, reduce compliance risks and ensure that products can enter and remain in the Hong Kong market.
Q499 · 跨境医药产品在香港申请药牌时，常见的合规难点有哪些？独立链接
Common challenges when applying for licences for cross-border pharmaceutical products include insufficient application documentation (such as missing clinical data or ingredient information), labels and package inserts that do not meet local requirements, complex import licensing procedures and lengthy approval periods. Language requirements, special formulations and ingredient controls also pose challenges. Rengangyongsheng (Hong Kong) Limited helps clients overcome these difficulties and expedite the approval process by clarifying application procedures, pre-screening documentation for completeness and providing local compliance advice.
Q500 · 仁港永胜对中成药及保健品的行业未来发展有哪些见解？独立链接
Rengangyongsheng (Hong Kong) Limited considers that demand for proprietary Chinese medicines and health supplements in the Hong Kong market is growing steadily, with consumers increasingly seeking high quality and safety assurance. In future, the sector will place greater emphasis on scientific validation, standardised manufacturing and digital compliance management. Cross-border trade will benefit from policy optimisation and greater regulatory transparency. We recommend that businesses embrace innovation, strengthen communication with regulators, and improve product quality and compliance systems to address changing market conditions and regulatory requirements and gain a competitive edge.